

## **CLAIM AMENDMENTS**

1-34. (Canceled)

35. (New) A pharmaceutical composition comprising:

a therapeutically effective amount of cilostazol;

a solubilizer; and

a release modulator;

wherein the release of cilostazol and solubilizer are synchronized.

36. (New) The pharmaceutical composition of Claim 35, wherein the solubilizer is a polyoxyethylene-polyoxypropylene block copolymer, a cyclodextrin or cyclodextrin derivative, a fatty acid or fatty acid derivative, a tocol derivative or mixtures thereof.

37. (New) The pharmaceutical composition of Claim 36, wherein the tocol derivative is a  $\alpha$ -tocopherol ester, a polyethoxylated  $\alpha$ -tocopherol ester or mixtures thereof.

38. (New) The pharmaceutical composition of Claim 37, wherein the tocol derivative is  $\alpha$ -tocopherol,  $\alpha$ -tocopherol acetate,  $\alpha$ -tocopherol nicotinoate,  $\alpha$ -tocopherol succinate,  $\alpha$ -tocopherol polyethyleneglycol (200-8000) succinate,  $\alpha$ -tocopherol polyethyleneglycol 400 succinate,  $\alpha$ -tocopherol polyethylene glycol 1000 succinate, d- $\alpha$ -tocopherol polyethylene glycol 1000 succinate, dl- $\alpha$ -tocopherol polyethylene glycol 1000 succinate or mixtures thereof.

39. (New) The pharmaceutical composition of Claim 36, wherein the fatty acid or fatty acid derivative is an ester with glycerol, propylene glycol, sorbitol, sucrose, glucose, polyethylene glycol, an alpha-hydroxy acid or mixtures thereof.

40. (New) The pharmaceutical composition of Claim 39, wherein the ester is a polyoxyl castor oil derivative, a PEG-8 caprylic/capric glyceride, a polysorbate, sorbitan monooleate, a medium chain mono-, di-, or triglyceride, an acetylated monoglyceride, a linoleoyl macroglyceride, a lauroyl macrogol-32 glyceride or mixtures thereof.

41. (New) The pharmaceutical composition of Claim 39, wherein the ester is polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-8 caprylic/capric glycerides, sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, PEG-20 sorbitan monooleate, glyceryl mono/dioleate, glyceryl caprylate/caprinate, caprylic acid mono/diglycerides, mono- and diacetylated monoglycerides, linoleoyl macroglycerides, caprylocaproyl macroglycerides, lauroyl macrogol-32 glycerides, propylene glycol monolaurate, propylene glycol monocaprylate.

42. (New) The pharmaceutical composition of Claim 35, wherein the release modulator is an osmotic pump, a slowly dissolving salt of a complex, an erodible matrix, an ion exchange resin, a wax, an insoluble carrier, a polymeric matrix, a polymeric coating, a fatty alcohol, a fatty alcohol derivative, fatty acid or fatty acid derivative or a tocol derivative.

43. (New) The pharmaceutical composition of Claim 42, wherein the release modulator is a polymeric matrix, a polymeric coating, a wax, a fatty alcohol, a fatty alcohol derivative, a fatty acid or fatty acid derivative, a tocol derivative or mixtures thereof.

44. (New) The pharmaceutical composition of Claim 43, wherein the polymeric matrix or polymeric coating is a cellulose derivative, an acrylic polymer, a

polyvinylpyrrolidone copolymer, a shellac, polyvinyl acetyl phthalate, a high molecular weight polysaccharide gum or mixtures thereof.

45. (New) The pharmaceutical composition of Claim 43, wherein the tocol derivative is  $\alpha$ -tocopherol,  $\alpha$ -tocopherol acetate,  $\alpha$ -tocopherol nicotinoate,  $\alpha$ -tocopherol succinate,  $\alpha$ -tocopherol polyethyleneglycol succinate,  $\alpha$ -tocopherol polyethylene glycol 400 succinate or mixtures thereof.

46. (New) The pharmaceutical composition of Claim 43, wherein the release modulator is microcrystalline wax, hydrogenated vegetable oil, glycerol dibehenate, glycerol distearate, glycerol dipalmitate, glycerol palmitostearate, a cellulose derivative, a lauroyl macrogol-32 glyceride, a stearyl macrogol-32 glyceride, calcium steroyl lactylate, stearic acid, stearyl alcohol, sucrose distearate, sucrose palmitate, sucrose dipalmitate, sorbitan monooleate, yellow wax, white wax, nonionic emulsifying wax, carnauba wax, microcrystalline wax, cetyl ester wax or mixtures thereof.

47. (New) The pharmaceutical composition of Claim 35, wherein the release is controlled over an extended period of time.

48. (New) The pharmaceutical composition of Claim 47, wherein the period of time is more than about 1 hour.

49. (New) The pharmaceutical composition of Claim 48, wherein the period of time is more than about 2 hours.

50. (New) The pharmaceutical composition of Claim 49, wherein the period of time is between about 2 hours and about 24 hours.

51. (New) The pharmaceutical composition of Claim 35, wherein the release of cilostazol and solubilizer are synchronized with a correlation coefficient of greater than about 0.80.

52. (New) The pharmaceutical composition of Claim 35 including one or more additives.

53. (New) The pharmaceutical composition of Claim 35 in which the amount of solubilizer is from about 15%w/w to about 95% w/w of the composition, the amount of release modulator is from about 1% to 50% w/w of the composition, and the amount of cilostazol is from about 0.5% to 50% w/w of the composition.

54. (New) The pharmaceutical composition of Claim 35, wherein the solubilizer is d- $\alpha$ -tocopherol polyethylene glycol 1000 succinate and the release modulator is  $\alpha$ -tocopherol succinate.

55. (New) The pharmaceutical composition of Claim 54 including one or more additives.

56. (New) The pharmaceutical composition of Claim 55, wherein the solubilizer is d- $\alpha$ -tocopherol polyethylene glycol 1000 succinate, the release modulator is  $\alpha$ -tocopherol succinate and the additive is polyethylene glycol.

57. (New) The pharmaceutical composition of Claim 35, wherein the solubilizer is polyoxyl 40 hydrogenated castor oil and the release modulator is hydroxypropylmethylcellulose.

58. (New) The pharmaceutical composition of Claim 35, wherein the solubilizer is polyoxyl 40 hydrogenated castor oil and the release modulator is glycerol dibehenate, glycerol palmitostearate, glycerol distearate, or mixtures thereof.

59. (New) An oral dosage form comprising:

a therapeutically effective amount of cilostazol;

a solubilizer; and

a release modulator;

wherein the release of cilostazol and solubilizer are synchronized.

60. (New) A solid oral dosage form comprising:

a therapeutically effective amount of cilostazol;

a solubilizer; and

a release modulator;

wherein the release of cilostazol and solubilizer are synchronized.

61. (New) The dosage form of Claim 60, wherein the dosage form is a capsule.